Immunoglobulin National Society (IgNS) 9th National Conference 2020

Virtual Event

Healix is excited to present our research data on Cutaquig® at the Immunoglobulin National Society (IgNS) 9th National Conference 2020. Speak with presenting author Lucinda J. Van Anglen, B.S., Pharm.D., during the IgNS Poster Session on Monday, October 26, from 3:00 to 4:30 p.m. EST for a live discussion at this year’s immersive virtual conference.

Real-World Evaluation of Efficacy and Tolerability of Immune Globulin Subcutaneous 16.5% in the Treatment of Patients with Primary Immunodeficiency

Lucinda J. Van Anglen, PharmD1; Richard F. Herrscher, MD, FACAAI2; Jeffrey W. Langford, MD, AE-C3; Samantha A. Mehta, PharmD1
1Healix Infusion Therapy, LLC, Sugar Land, TX; 2AIR Care, Dallas, Texas; 3Langford Allergy, LLC, Macon, GA

Learn more about our outcomes research and how Healix can help you establish an office infusion center or outsource the management of an existing operation by contacting us today!


View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.